Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marzena, Wieczorkowska"'
Autor:
Jerzy Gebicki, Marzena Wieczorkowska
Publikováno v:
Cell Death Discovery
Cell Death Discovery, Vol 6, Iss 1, Pp 1-2 (2020)
Cell Death Discovery, Vol 6, Iss 1, Pp 1-2 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::550e59fddb9d7061458365abf901aae5
Publikováno v:
Clinical and Experimental Dermatology. 30:632-635
Rosacea is a chronic facial dermatosis with a progressive course, which is characterized by the presence of erythema, papules, pustules, telangiectasias and sebaceous gland hyperplasia. However, the aetiology is still unknown; genetic predisposition,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88081787430001c54361569fc0f2d21d
https://doi.org/10.1111/j.1365-2230.2005.01908.x
https://doi.org/10.1111/j.1365-2230.2005.01908.x
Autor:
Marzena, Wieczorkowska, Piotr, Szajerski, Radosław, Michalski, Jan, Adamus, Andrzej, Marciniak, Jerzy, Gebicki, Ewa, Ciesielska, Leszek, Szmigiero, Ewa, Lech-Marańda, Anna, Szmigielska-Kapłon, Tadeusz, Robak
Publikováno v:
Pharmacological reports : PR. 59(2)
The objective of this work was to evaluate the relationship between chemical reactivity of 3-substituted pyridinium salts and their cytotoxic properties against murine leukemia L1210. Chemical reactivity of pyridinium salts towards NADH oxidation fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7a992cc092573350af82f9da8f89464
https://pubmed.ncbi.nlm.nih.gov/17556800
https://pubmed.ncbi.nlm.nih.gov/17556800
Autor:
Jerzy Gebicki, Jan Adamus, Leszek Szmigiero, Ewa Ciesielska, Joanna Celińska, Marzena Wieczorkowska, Andrzej Marcinek, Jacek Zielonka
Publikováno v:
Free radical research. 37(11)
It is shown that NADH can be effectively oxidized by 1-methyl-3-nitropyridine in non-enzymatic and enzyme-mediated processes. Mechanistic issues of these reactions are discussed. These processes seem to contribute to the observed cytotoxicity of 1-me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea317db39f2acc0da086f2b97815c57
https://pubmed.ncbi.nlm.nih.gov/14703727
https://pubmed.ncbi.nlm.nih.gov/14703727
Autor:
Imelda Parker, Marzena Wieczorkowska, Maeve Leahy, Brian Hennessy, Johanna Kelly, David O'Brien, Gerard Crotty, Mary R. Cahill, Amjad Hayat, Elisabeth Vandenberghe, Fionnuala Keane, Helen Enright, Fiona Quinn
Publikováno v:
Blood. 120:1791-1791
Abstract 1791 Six courses of FCR is considered standard therapy for fit, non-(17p) deleted patients with Chronic Lymphocytic Leukaemia (CLL), however the optimal dose of Rituximab in combined chemotherapy for CLL or the number of FCR courses required
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::111bdb3f089aa9c1973156bf3360fc57
https://doi.org/10.1182/blood.v120.21.1791.1791
https://doi.org/10.1182/blood.v120.21.1791.1791
Autor:
Philipp le Coutre, Cliona McDowell, Eibhlin Conneally, Michael O'Dwyer, Mary Frances McMullin, Karine Egan, Stephen E. Langabeer, Brian Moulton, Ronan T. Swords, Arnon Nagler, Francis J. Giles, Marzena Wieczorkowska
Publikováno v:
Blood. 118:3774-3774
Abstract 3774 BACKGROUND/METHODS: Data from the ENESTnd phase III trial showed superiority of nilotinib over imatinib leading to accelerated approval of nilotinib as initial treatment of ECPCML at a dose of 300mg BID. ICORG, the All-Ireland Cooperati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5398b71a36415df9500ab163eb0fea32
https://doi.org/10.1182/blood.v118.21.3774.3774
https://doi.org/10.1182/blood.v118.21.3774.3774
Autor:
Mary Frances McMullin, Cliona McDowell, Ronan T. Swords, Michael O'Dwyer, Brian Moulton, Philipp le Coutre, Eibhlin Conneally, Francis J. Giles, Stephen E. Langabeer, Karine Egan, Marzena Wieczorkowska
Publikováno v:
Blood. 116:3427-3427
Abstract 3427 Recently, early results of the ENESTnd phase III trial showing superiority of nilotinib over imatinib, led to accelerated approval of Nilotinib as initial treatment of ECP CML at a dose of 300mg BID. Independently, since December 2008,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1593789d81707778ebfa1075de401b8
https://doi.org/10.1182/blood.v116.21.3427.3427
https://doi.org/10.1182/blood.v116.21.3427.3427